- Previous Close
35.68 - Open
35.68 - Bid 36.19 x --
- Ask 36.49 x --
- Day's Range
34.97 - 37.80 - 52 Week Range
32.00 - 56.90 - Volume
43,385 - Avg. Volume
74,494 - Market Cap (intraday)
623.94M - Beta (5Y Monthly) 0.67
- PE Ratio (TTM)
-- - EPS (TTM)
-1.87 - Earnings Date May 19, 2025 - May 23, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It also supplies SPF lab animals; breeds and distributes rodent models; and offers custom rodent models, and stem cell products, as well as lab animal diets. In addition, the company provides regulatory and non-regulatory IND preclinical services; screening and evaluating molecules for various pharmacological properties; and designs and develops of syngeneic / xenograft models for evaluation of anti-cancer agents evaluation. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
www.vivobio.comRecent News: VIVOBIOT.BO
View MorePerformance Overview: VIVOBIOT.BO
Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIVOBIOT.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIVOBIOT.BO
View MoreValuation Measures
Market Cap
612.44M
Enterprise Value
1.18B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.25
Price/Book (mrq)
1.02
Enterprise Value/Revenue
2.55
Enterprise Value/EBITDA
4.61
Financial Highlights
Profitability and Income Statement
Profit Margin
15.08%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
461.4M
Net Income Avi to Common (ttm)
69.56M
Diluted EPS (ttm)
-1.87
Balance Sheet and Cash Flow
Total Cash (mrq)
13.7M
Total Debt/Equity (mrq)
96.79%
Levered Free Cash Flow (ttm)
--